Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2020 Aug 11

PMID 32775327

Citations 32

Authors

Christopher Montemagno

Gilles Pages

Affiliations

Soon will be listed here.

Abstract

Angiogenesis, the formation of new blood vessels from preexisting one, represents a critical process for oxygen and nutrient supply to proliferating cells, therefore promoting tumor growth and metastasis. The Vascular Endothelial Growth Factor (VEGF) pathway is one of the key mediators of angiogenesis in cancer. Therefore, several therapies including monoclonal antibodies or tyrosine kinase inhibitors target this axis. Although preclinical studies demonstrated strong antitumor activity, clinical studies were disappointing. Antiangiogenic drugs, used to treat metastatic patients suffering of different types of cancers, prolonged survival to different extents but are not curative. In this review, we focused on different mechanisms involved in resistance to antiangiogenic therapies from early stage resistance involving mainly tumor cells to late stages related to the adaptation of the microenvironment.

Citing Articles

Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.

Al-Hussaini M, Al-Ani A, Amarin J, Al Sharie S, Obeidat M, Musharbash A Cancers (Basel). 2025; 17(4).

PMID: 40002185 PMC: 11852727. DOI: 10.3390/cancers17040590.

Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies.

Goncalves M, Warwas K, Meyer M, Schwartz-Albiez R, Bulbuc N, Zornig I Cancers (Basel). 2025; 16(24.

PMID: 39766150 PMC: 11674949. DOI: 10.3390/cancers16244251.

Vascular endothelial growth factor A inhibition remodels the transcriptional signature of lipid metabolism in psoriasis non-lesional skin in 12 h ex vivo culture.

Luengas-Martinez A, Ismail D, Paus R, Young H Skin Health Dis. 2024; 4(6):e471.

PMID: 39624732 PMC: 11608907. DOI: 10.1002/ski2.471.

Contemporaneous Inflammatory, Angiogenic, Fibrogenic, and Angiostatic Cytokine Profiles of the Time-to-Tumor Development by Cancer Cells to Orchestrate Tumor Neovascularization, Progression, and Metastasis.

Skapinker E, Aucoin E, Kombargi H, Yaish A, Li Y, Baghaie L Cells. 2024; 13(20.

PMID: 39451257 PMC: 11506673. DOI: 10.3390/cells13201739.

Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression.

Kaviyaprabha R, R K, Miji T, Tv M, Suseela R, R S Curr Cancer Drug Targets. 2024; 25(2):183-203.

PMID: 39289946 DOI: 10.2174/0115680096321287240826065718.

References

Croci D, Cerliani J, DAlotto-Moreno T, Mendez-Huergo S, Mascanfroni I, Dergan-Dylon S . Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014; 156(4):744-58. DOI: 10.1016/j.cell.2014.01.043. View

Wolf A, Langmann T . Anti-VEGF-A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study. EMBO Mol Med. 2019; 11(5). PMC: 6505573. DOI: 10.15252/emmm.201910362. View

Hirota K, Semenza G . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59(1):15-26. DOI: 10.1016/j.critrevonc.2005.12.003. View

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Comunanza V, Bussolino F . Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol. 2017; 5:101. PMC: 5725406. DOI: 10.3389/fcell.2017.00101. View

Chung A, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D . Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol. 2012; 227(4):404-16. DOI: 10.1002/path.4052. View

McIntyre A, Harris A . Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med. 2015; 7(4):368-79. PMC: 4403040. DOI: 10.15252/emmm.201404271. View

10.

Ndiaye P, Dufies M, Giuliano S, Douguet L, Grepin R, Durivault J . VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics. 2019; 9(3):661-675. PMC: 6376471. DOI: 10.7150/thno.27794. View

11.

Delgado-Bellido D, Serrano-Saenz S, Fernandez-Cortes M, Oliver F . Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer. 2017; 16(1):65. PMC: 5359927. DOI: 10.1186/s12943-017-0631-x. View

12.

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

13.

Wei Y, Zhou F, Zhou H, Huang J, Yu D, Wu G . Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription. Int J Cancer. 2018; 143(3):657-667. DOI: 10.1002/ijc.31349. View

14.

Xin X, Yang S, Ingle G, Zlot C, RANGELL L, Kowalski J . Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001; 158(3):1111-20. PMC: 1850376. DOI: 10.1016/S0002-9440(10)64058-8. View

15.

Walsh D . Pathophysiological mechanisms of angiogenesis. Adv Clin Chem. 2007; 44:187-221. DOI: 10.1016/s0065-2423(07)44006-9. View

16.

Motzer R, Hutson T, Glen H, Michaelson M, Molina A, Eisen T . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9. View

17.

Joseph J, Harishankar M, Pillai A, Devi A . Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol. 2018; 80:23-32. DOI: 10.1016/j.oraloncology.2018.03.004. View

18.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

19.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K . Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019; 12(1):27. PMC: 6417086. DOI: 10.1186/s13045-019-0718-5. View

20.

Sparmann A, Bar-Sagi D . Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004; 6(5):447-58. DOI: 10.1016/j.ccr.2004.09.028. View